Trius says late-stage trial for skin infection drug meets study endpoint
Posted on December 19, 2011 at 13:30 PM EST
Orlando, FL - December 19, 2011 (Investorideas.com Newswire) - The Street Beat commentary - Trius Therapeutics, Inc. (Nasdaq:TSRX) announced today that tedizolid phosphate met the primary objective of non-inferiority for the efficacy outcome of early clinical response versus the comparator linezolid (Zyvox(R)) in patients with acute bacterial skin and skin structure infections (ABSSSI).